ImmunityBio: The Story Surrounding Anktiva So Far (NASDAQ:IBRX)

ImmunityBio, Inc. ( IBRX ) stock has been on a very bullish run. The investor confidence comes from the potential of a chemo‑free immunotherapy platform, which is led by Anktiva. The short idea here is that Anktiva is an IL‑15 superagonist that fuelsI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foun ...